Cover Image
市場調查報告書

HIV-1 感染疾病 - 開發平台分析

HIV-1 Infection - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 232817
出版日期 內容資訊 英文 406 Pages
訂單完成後即時交付
價格
Back to Top
HIV-1 感染疾病 - 開發平台分析 HIV-1 Infection - Pipeline Review, H2 2015
出版日期: 2015年12月23日 內容資訊: 英文 406 Pages
簡介

HIV-1是人體免疫不全病毒-1引起的反轉錄病毒感染疾病,是以血液為媒介的病毒,藉由性交或共用注射針筒、血液接觸傳染。症狀有發燒,疲勞,肌肉痛,淋巴節的發炎,倦怠感,頭痛,噁心等。愛滋病病毒第一型感染可藉由包含ELISA在內的特別篩檢法診斷。治療方法為使用抗逆轉錄病毒類藥物。

本報告提供HIV-1 感染疾病的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍
  • HIV-1 感染疾病 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發企業

  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals, Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • United Biomedical, Inc.
  • 化學和血清療法學會
  • Aphios Corporation
  • Pfizer Inc.
  • Koronis Pharma, Inc.
  • Crucell N.V.
  • GeoVax Labs, Inc.
  • Enzo Biochem, Inc.
  • ConjuChem Biotechnologies Inc.
  • Critical Outcome Technologies Inc.
  • TaKaRa BIO Inc.
  • Bionor Pharma ASA
  • Quantum Pharmaceuticals
  • Italfarmaco S.p.A.
  • Vironova AB
  • ViroStatics, srl
  • Argos Therapeutics, Inc.
  • Myrexis, Inc.
  • GeneCure LLC
  • Tobira Therapeutics, Inc.
  • Pharis Biotec GmbH
  • Medestea Research & Production S.p.A.
  • ViiV Healthcare Limited
  • RFS Pharma, LLC
  • Vichem Chemie Research Ltd.
  • AltraVax Inc.
  • TaiMed Biologics Inc.
  • InnaVirVax SA
  • Valens Therapeutics, Inc.
  • Susavion Biosciences, Inc.
  • AbbVie Inc.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (dolutegravir + abacavir sulphate + lamivudine)
  • (cobicistat + darunavir)
  • dapivirine
  • (elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide)
  • ALVAC-HIV vCP1521 + AIDSVAX B/B
  • (atazanavir sulfate + cobicistat)
  • (cobicistat + darunavir)
  • ABT-450/r + ABT-267 + dasabuvir
  • pGA2/JS7 DNA Vaccine + Recombinant Modified Vaccinia Ankara/HIV62B Vaccine
  • censavudine
  • amdoxovir
  • cenicriviroc
  • AGS-004
  • (didanosine + hydroxyurea)
  • Vacc-4x
  • BMS-663068
  • TMC-310911
  • KP-1461
  • VRC-HIVDNA016-00-VP Vaccine
  • HIV-1 Tat Vaccine
  • UB-421
  • GSK-732462
  • doravirine
  • VAC-3S
  • (darunavir + cobicistat + emtricitabine + tenofovir alafenamide)
  • BMS-955176
  • HGTV-43
  • Dendritic Cell Vaccine
  • VRC-HIVADV014-00-VP Vaccine
  • TUTI-16
  • VRC-HIVDNA016-00-VP Vaccine
  • Tat Oyi Vaccine
  • Ad26.ENVA.01 Vaccine
  • rilpivirine
  • BIIR/ANRS-HIVax-001
  • PENNVAX-B DNA Vaccine
  • Ad5.ENVA.48 HIV-1 vaccine
  • MVA-B Vaccine
  • DNA Vaccine + Recombinant Adenoviral Subtype 5 + Recombinant Adenoviral Subtype 35
  • MVA.HIVconsv Vaccine
  • rAd5 Env A Vaccine
  • KD-247
  • aldesleukin + CD-4 Zeta Gene-Modified T Cells
  • Plasmid DNA-MVA Prime Boost HIV-1 Vaccine
  • APH-0812
  • Replication Defective HIV-1 Vaccine
  • Clade B HIV Vaccine
  • MazF-Based HIV-1 Gene Therapy
  • AFO-18-CAF01 Vaccine
  • TMB-657
  • VRC-01
  • DNA-HIV-PT123 + NYVAC-HIV-PT1 + NYVAC-HIV-PT4
  • HIV Vaccine
  • Teravac HIV-1 Vaccine
  • rAd5HVR48 HIV-1 Vaccine
  • Retroviral Transduced T-Cell Therapy For HIV
  • Anti-HIV Monoclonal Antibody
  • L-644
  • HIV-1 Integrase Inhibitors
  • DAC-HIV
  • Leukothera
  • Small Molecules to Inhibit CDK9 for HIV-1 Infection
  • AT-96
  • GS-8374
  • HIV-1 Vaccine
  • DS-003
  • M48-U1
  • Azuvirins
  • Mutated tRNAs
  • HIV Vaccine
  • Cell Therapy for HIV-1 Infection
  • Peptides Targeting TAR for HIV-1 Infection
  • HIV-1 Integrase Inhibitor for Viral Infections
  • HIV-1 Vaccine
  • F2
  • SVC-2
  • SV6-B
  • SV6-C
  • SVH1-C
  • Nuclear Export Inhibitors
  • BMS-585248
  • VRC-03 Vaccine
  • HIV-1 Mosaic Vaccine
  • Tropolone Derivatives
  • SIV Vaccine
  • Cyclic V3 Peptide Vaccine
  • Drug Targeting HIV-1 Reverse Transcriptase
  • INS Peptide
  • INRS Peptide
  • Compounds Mimicking CD-4 Protein
  • Maturation Inhibitor for HIV-1
  • CCL-14
  • givinostat
  • HIV-1 Program
  • aminoquinuride
  • Drug For HIV-1 Infection
  • PF-46396
  • PAV-8802 Series
  • Small Molecules to Inhibit p25 and gp120 for HIV-1 Infection
  • RC-100b
  • Polyvalent HIV-1 Glycoprotein DNA Vaccines
  • Drugs to Inhibit HIV-1 Protease for HIV-1 Infection
  • RN-18
  • Ank(GAG)1D4
  • 5-HN
  • Drug Targeting Glycoprotein 41
  • Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection
  • SVH1-D
  • Compound-30
  • Compound-7
  • Drug For HIV-1
  • Small Molecule for HIV-1 Infection
  • Nelfinavir Analogue
  • Drugs Targeting HIV-1 Reverse Transcriptase for HIV-1 Infection
  • Polypeptide For HIV-1
  • Drug For HIV-1 Infection
  • GRL-0519
  • VRC-02 Vaccine
  • Compound 11-b
  • Drug to Inhibit Vif Protein for HIV-1 Infection
  • Compound X
  • Recombinant Peptides for HIV-1 Infection and STDs
  • Drugs to Inhibit Reverse Transcriptase for Viral Infections
  • AH-0109

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7066IDB

Summary

Global Markets Direct's, 'HIV-1 Infection - Pipeline Review, H2 2015', provides an overview of the HIV-1 Infection's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of HIV-1 Infection
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for HIV-1 Infection and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the HIV-1 Infection pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • HIV-1 Infection Overview
  • Therapeutics Development
  • HIV-1 Infection - Therapeutics under Development by Companies
  • HIV-1 Infection - Therapeutics under Investigation by Universities/Institutes
  • HIV-1 Infection - Pipeline Products Glance
  • HIV-1 Infection - Products under Development by Companies
  • HIV-1 Infection - Products under Investigation by Universities/Institutes
  • HIV-1 Infection - Companies Involved in Therapeutics Development
  • HIV-1 Infection - Therapeutics Assessment
  • Drug Profiles
  • HIV-1 Infection - Recent Pipeline Updates
  • HIV-1 Infection - Dormant Projects
  • HIV-1 Infection - Discontinued Products
  • HIV-1 Infection - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for HIV-1 Infection, H2 2015
  • Number of Products under Development for HIV-1 Infection - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Development by Companies, H2 2015 (Contd..6)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
  • HIV-1 Infection - Pipeline by AltraVax Inc., H2 2015
  • HIV-1 Infection - Pipeline by Aphios Corporation, H2 2015
  • HIV-1 Infection - Pipeline by Argos Therapeutics, Inc., H2 2015
  • HIV-1 Infection - Pipeline by Arno Therapeutics, Inc., H2 2015
  • HIV-1 Infection - Pipeline by Beth Israel Deaconess Medical Center, Inc., H2 2015
  • HIV-1 Infection - Pipeline by Bionor Pharma ASA, H2 2015
  • HIV-1 Infection - Pipeline by Biosantech SA, H2 2015
  • HIV-1 Infection - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • HIV-1 Infection - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • HIV-1 Infection - Pipeline by Chipscreen Biosciences Ltd, H2 2015
  • HIV-1 Infection - Pipeline by CompleGen, Inc., H2 2015
  • HIV-1 Infection - Pipeline by Critical Outcome Technologies Inc., H2 2015
  • HIV-1 Infection - Pipeline by Cytodyn Inc., H2 2015
  • HIV-1 Infection - Pipeline by Dong-A ST Co., Ltd., H2 2015
  • HIV-1 Infection - Pipeline by Enzo Biochem, Inc., H2 2015
  • HIV-1 Infection - Pipeline by Evofem, Inc., H2 2015
  • HIV-1 Infection - Pipeline by FIT Biotech Oy, H2 2015
  • HIV-1 Infection - Pipeline by Formune S.L., H2 2015
  • HIV-1 Infection - Pipeline by Frontier Biotechnologies Co., Ltd, H2 2015
  • HIV-1 Infection - Pipeline by GeneCure LLC, H2 2015
  • HIV-1 Infection - Pipeline by Genetic Immunity, Inc, H2 2015
  • HIV-1 Infection - Pipeline by Gilead Sciences, Inc., H2 2015
  • HIV-1 Infection - Pipeline by GlaxoSmithKline Plc, H2 2015
  • HIV-1 Infection - Pipeline by H-Phar S.A., H2 2015
  • HIV-1 Infection - Pipeline by Heat Biologics, Inc., H2 2015
  • HIV-1 Infection - Pipeline by InnaVirVax SA, H2 2015
  • HIV-1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
  • HIV-1 Infection - Pipeline by Johnson & Johnson, H2 2015
  • HIV-1 Infection - Pipeline by Merck & Co., Inc., H2 2015
  • HIV-1 Infection - Pipeline by Mologen AG, H2 2015
  • HIV-1 Infection - Pipeline by Mymetics Corporation, H2 2015
  • HIV-1 Infection - Pipeline by Myrexis, Inc., H2 2015
  • HIV-1 Infection - Pipeline by Novartis AG, H2 2015
  • HIV-1 Infection - Pipeline by Oncolys BioPharma Inc., H2 2015
  • HIV-1 Infection - Pipeline by Oncovir, Inc., H2 2015
  • HIV-1 Infection - Pipeline by OyaGen Inc., H2 2015
  • HIV-1 Infection - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015
  • HIV-1 Infection - Pipeline by Pfizer Inc., H2 2015
  • HIV-1 Infection - Pipeline by Pharis Biotec GmbH, H2 2015
  • HIV-1 Infection - Pipeline by Profectus BioSciences, Inc., H2 2015
  • HIV-1 Infection - Pipeline by Sanofi Pasteur SA, H2 2015
  • HIV-1 Infection - Pipeline by Spider Biotech, H2 2015
  • HIV-1 Infection - Pipeline by Susavion Biosciences, Inc., H2 2015
  • HIV-1 Infection - Pipeline by TaiMed Biologics Inc., H2 2015
  • HIV-1 Infection - Pipeline by Takara Bio Inc., H2 2015
  • HIV-1 Infection - Pipeline by TGV-Laboratories, H2 2015
  • HIV-1 Infection - Pipeline by Theravectys SA, H2 2015
  • HIV-1 Infection - Pipeline by Tobira Therapeutics, Inc., H2 2015
  • HIV-1 Infection - Pipeline by United Biomedical, Inc., H2 2015
  • HIV-1 Infection - Pipeline by Vichem Chemie Research Ltd., H2 2015
  • HIV-1 Infection - Pipeline by ViiV Healthcare Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • HIV-1 Infection Therapeutics - Recent Pipeline Updates, H2 2015
  • HIV-1 Infection - Dormant Projects, H2 2015
  • HIV-1 Infection - Dormant Projects (Contd..1), H2 2015
  • HIV-1 Infection - Dormant Projects (Contd..2), H2 2015
  • HIV-1 Infection - Dormant Projects (Contd..3), H2 2015
  • HIV-1 Infection - Dormant Projects (Contd..4), H2 2015
  • HIV-1 Infection - Dormant Projects (Contd..5), H2 2015
  • HIV-1 Infection - Dormant Projects (Contd..6), H2 2015
  • HIV-1 Infection - Dormant Projects (Contd..7), H2 2015
  • HIV-1 Infection - Dormant Projects (Contd..8), H2 2015
  • HIV-1 Infection - Dormant Projects (Contd..9), H2 2015
  • HIV-1 Infection - Dormant Projects (Contd..10), H2 2015
  • HIV-1 Infection - Discontinued Products, H2 2015
  • HIV-1 Infection - Discontinued Products (Contd..1), H2 2015

List of Figures

  • Number of Products under Development for HIV-1 Infection, H2 2015
  • Number of Products under Development for HIV-1 Infection - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top